Calamos Advisors
PRVB

Calamos Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Calamos Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-96,119
Closed -$1.36M – 753
2020
Q2 		$1.36M Buy
+96,119
New +$1.21M 0.01% 614

Other funds holding PRVB

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Calamos Advisors's PRVB Position: Q3 2020 in Review

Calamos Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q3 2020, closing a stake of 96,119 shares — an estimated $1.36M sold.

Calamos Advisors first reported a position in PRVB in Q2 2020 and held it in 1 quarter. The position peaked at $1.36M in Q2 2020. 100 funds tracked by Wall St. Rank hold PRVB as of Q3 2020.

  • Calamos Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Calamos Advisors sold 96,119 Provention Bio, Inc. Common Stock shares in Q3 2020, an estimated $1.36M.
  • Calamos Advisors first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Calamos Advisors's Provention Bio, Inc. Common Stock position peaked at $1.36M in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2020.

Based on Calamos Advisors's 13F filing for Q3 2020, filed 26 Oct 2020.